An introduction to ACTEMRA®/RoACTEMRA® (tocilizumab)
This website is intended as an extensive resource for healthcare professionals outside the US with an interest in rheumatoid arthritis (RA) and its treatment with ACTEMRA/RoACTEMRA (tocilizumab), a first-in-class agent with a novel mechanism of action that targets the interleukin-6 (IL-6) receptor.
The product is known as RoACTEMRA in the EU and Mexico and as ACTEMRA in the US and other countries.
This site contains a wealth of resources including the mechanism of action, safety and efficacy information from key clinical trials, including the use of ACTEMRA/RoACTEMRA in monotherapy and dosage and administration details. There is also a useful resource section containing a range of downloadable materials on RA and ACTEMRA/RoACTEMRA.
Now approved for sJIA
ACTEMRA/RoACTEMRA is the first and only approved treatment for systemic juvenile idiopathic arthritis (sJIA). This section provides a variety of information and materials for both patients and healthcare professionals relating to the use of ACTEMRA/RoACTEMRA in the management of sJIA. More...
About ACTEMRA
This section contains detailed scientific and medical information on ACTEMRA/RoACTEMRA, including the mechanism of action, dosage and administration details, and safety and efficacy information from key clinical trials. More...
Resources
This section provides a wealth of useful information and practical items for both patients and healthcare professionals relating to the management of rheumatoid arthritis (RA) and the use of ACTEMRA/RoACTEMRA. More...